NCT02484391 2024-09-19
CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Granulocytic Sarcoma
Wake Forest University Health Sciences
Phase 1 Completed
Clinical Trials
7 trialsNCT02168140 2024-02-13
CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma
Wake Forest University Health Sciences
Phase 1 Completed
NCT02232152 2023-08-07
CPI-613 and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery
Wake Forest University Health Sciences
Phase 1 Completed
NCT01839981 2018-12-27
CPI-613 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
Wake Forest University Health Sciences
Phase 1 Completed
NCT01768897 2018-07-03
CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Wake Forest University Health Sciences
Phase 1 Completed
NCT01931787 2018-07-03
CPI-613 in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer
Wake Forest University Health Sciences
Phase 1 Completed
NCT00741403 2016-12-29
A Open Label Phase I/II Clinical Trial to Evaluate CPI-613 in Patients With Advanced Malignancies
Cornerstone Pharmaceuticals
Phase 1 Completed